

*( Clinical data, Phase 3 )*



Neurocrine Biosciences advances NBI-III7568 into Phase 3 as a potential treatment for adults with schizophrenia

*( Collaboration, commercialization )*



Henlius secures upfront \$31M in Sandoz deal for HLX13 biosimilar, aiming to expand access in immuno-oncology

*( Acquisition )*



Synhale Therapeutics expands pipeline with telaglenastat acquisition, advancing into Phase 2 for pulmonary hypertension

*( FDA, NDA )*



Novo Nordisk's oral semaglutide 25 mg accepted for FDA review as first potential oral GLP-1 therapy for obesity

